Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Suchy Las

9 clinical trials in Suchy Las, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Suchy Las at a glance
9
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

9 trials in Suchy Las

Open in trial search

A study to evaluate the effectiveness and safety of DT-101 in adults with major depressive disorder

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Draig Therapeutics Limited

Study of milsaperidone as an additional treatment for adults with Major Depressive Disorder who are already taking antidepressants

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:(1S)-1-[4-[3-[4-(6-FLUORO-1,2-BENZOXAZOL-3-YL)PIPERIDIN-1-YL]PROPOXY]-3-METHOXYPHENYL]ETHANOL
  • Sponsor:Vanda Pharmaceuticals Netherlands B.V.

Major depression

Not recruiting

Testing Ulotaront Added to Antidepressants for Adults with Major Depressive Disorder Who Did Not Respond Well to Initial Treatment

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Citalopram
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Major depression

Not recruiting

Study on the Safety and Effectiveness of Aticaprant with Antidepressants for Adults and Elderly with Major Depressive Disorder

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Major depression+1

Not recruiting

Study on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.

Major depression

Not recruiting

Study on the Effects of Psilocybin (COMP360) for Adults with Treatment-Resistant Depression

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Psilocybine
  • Sponsor:Compass Pathfinder Limited

Major depression

Not recruiting

Study on Aticaprant for Adults with Major Depressive Disorder and Anhedonia Not Responding to Antidepressants

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Suchy Las

What the registry says about research in the country

01 Treatment-Resistant Depression Studies

Innovative research exploring COMP360 therapy for patients with treatment-resistant depression, focusing on improving depressive symptoms through targeted psychological support interventions.

  • Novel therapeutic approaches
  • Psychological support integration
  • Symptom improvement assessment

These trials aim to provide new hope for patients who haven't responded to conventional treatments.

02 Major Depressive Disorder Research

Comprehensive studies evaluating NMRA-335140 and other novel compounds for treating major depressive disorder, with both short-term efficacy and long-term safety assessments.

  • Daily treatment protocols
  • Long-term safety evaluation
  • Symptom reduction analysis

Multiple approaches are being investigated to enhance treatment outcomes for MDD patients.

03 Anhedonia-Focused Depression Studies

Specialized research examining aticaprant as an adjunctive therapy for patients with major depressive disorder complicated by moderate-to-severe anhedonia.

  • Combination therapy assessment
  • Relapse prevention strategies
  • Long-term effectiveness monitoring

These trials specifically target the challenging subset of depression with prominent anhedonia symptoms.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.